Development of in silico prediction method for idiosyncratic adverse reactions associated with HLA genotypes
| Project/Area Number |
16K15156
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Suzuki Hiroshi 東京大学, 医学部附属病院, 教授 (80206523)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
本間 雅 東京大学, 医学部附属病院, 講師 (60401072)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 薬剤反応性 / 薬理学 / 免疫学 / トランスレーショナルリサーチ |
|---|
| Outline of Final Research Achievements |
In the present study, we aimed to develop an in silico prediction method for interaction between HLA protein and drug molecules. At the beginning, we analyzed the binding site of carbamazepine to HLA-B*15:02, however; the binding of carbamazepine to HLA-B*15:02 protein surface, which was reported previously, was not reproducible and it seems not correct that carbamazepine binds to the molecular surface of HLA protein. We also evaluated the interaction between carbamazepine and corresponding TCR clonotype but the interaction was not detected. A series of experimental results indicated the possibility that presented antigen peptide is responsible for determining the interaction between carbamazepine and HLA protein.
|
Report
(3 results)
Research Products
(1 results)
